Dr. Brose Describes the DECISION Trial

Marcia S. Brose, MD, PhD
Published: Tuesday, Dec 03, 2013

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Brose explains that the DECISION trial was a placebo-controlled, randomized trial that tested the efficacy of sorafenib in patients with differentiated thyroid cancer that had progressed following radioactive iodine. These patients were randomized 1:1 to either sorafenib or placebo.

Brose says the results showed that the progression-free survival in the sorafenib arm was significantly increased to 10.8 months compared to 5.8 months in the placebo arm. This data is statistically significant with a hazard ratio of .587 and a P value of less than .0001.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Brose explains that the DECISION trial was a placebo-controlled, randomized trial that tested the efficacy of sorafenib in patients with differentiated thyroid cancer that had progressed following radioactive iodine. These patients were randomized 1:1 to either sorafenib or placebo.

Brose says the results showed that the progression-free survival in the sorafenib arm was significantly increased to 10.8 months compared to 5.8 months in the placebo arm. This data is statistically significant with a hazard ratio of .587 and a P value of less than .0001.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x